South Korea Insomnia Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists), By Sales Channel (Over-The-Counter (OTC) and Prescription Therapeutics), and South Korea Insomnia Therapeutics Market Insights, Industry Trend, Forecasts to 2035

South Korea Insomnia Therapeutics Market Insights Forecasts to 2035

• The South Korea Insomnia Therapeutics Market Size Was Estimated at USD 55.4 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.44% from 2025 to 2035
• The South Korea Insomnia Therapeutics Market Size is Expected to Reach USD 99.2 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the South Korea Insomnia Therapeutics Market Size is Anticipated to Reach USD 99.2 Million by 2035, Growing at a CAGR of 5.44% from 2025 to 2035. Insomnia is becoming more common due to several factors, such as rising stress levels, changing lifestyles, and an aging population.

Market Overview

The variety of goods and services used to treat insomnia, a sleep disorder marked by trouble falling asleep, staying asleep, or both, is included in the market for insomnia treatments. Both pharmaceutical (drugs) and non-pharmacological (such as cognitive behavioral therapy for insomnia, or CBT-I) treatments are available in this market. The increased incidence of sleep problems and growing knowledge of the negative effects of insomnia on general health are driving this expanding industry. People who receive effective therapies sleep better, which enhances their mood, general quality of life, and daytime functioning. Numerous health issues, including depression, diabetes, and heart disease, are associated with insomnia. These dangers can be reduced with effective therapy. Better sleep enables enhanced memory, focus, and decision-making, among other cognitive functions. A prevalent sleep problem that fuels the need for treatment options. The demand for non-pharmacological techniques is being driven by growing worries about the adverse effects of pharmaceuticals and a preference for alternative cures. The demand for treatments rises as a result of governments' active efforts to promote public awareness of insomnia and other sleep disorders.

Restraining Factors

Misconceptions about the seriousness of insomnia often lead to underdiagnosis and avoidance of treatment, thereby hampering market growth. Common side effects of insomnia medications such as daytime drowsiness, memory problems, drug dependence, and hallucinations reduce patient adherence and limit their usage. Additionally, high R&D and regulatory approval costs, along with competition from non-drug therapies like CBT-I, further hinder commercialization and profitability, slowing innovation and delaying the launch of new products.

Driving Factors       

The rising stress levels and lifestyle-induced sleep disorders, notably in aging and urban populations seeking relief. Rapid innovation, like dual orexin receptor antagonists and digital CBT-I, offers safer, personalized treatment. AI-enhanced diagnostics and telemedicine expand access and improve monitoring. Additionally, increasing mental health awareness, supportive reimbursement policies, and the introduction of novel prescription and OTC options bolster market expansion.

Report Coverage

This research report categorizes the market for South Korea insomnia therapeutics market based on various segments and regions forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea insomnia therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea insomnia therapeutics market.

Market Segmentation

The South Korea insomnia therapeutics market share is classified into type and sales channel.

• The benzodiazepines segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea insomnia therapeutics market is segmented by type into benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonists, and melatonin antagonists. Among these, the benzodiazepines segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. Benzodiazepines can help with acute stress-related sleeplessness. It suppresses slow-wave sleep, reduces sleep latency, and lengthens sleep by 30 to 90 minutes. Segmental growth is being driven by doctors' increased acceptance of medications because of their accessible availability and rapid results.

• The over-the-counter (OTC) segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea insomnia therapeutics market is segmented by sales channel into over-the-counter (OTC) and prescription therapeutics. Among these, the over-the-counter (OTC) segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The rising number of insomniac sufferers. OTC medications are readily available to people with acute insomnia and do not require a prescription. Patients with insomnia now have more individualized and efficient treatment options because to the development of combination therapies, which combine over-the-counter pharmaceuticals with prescription medications or non-pharmacological approaches.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea insomnia therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• OTC Products
• Sanofi
• Yuhan Corporation
• DongA ST
• Korea United Pharmaceutical
• JW Pharmaceutical
• Daewoong Pharmaceutical
• LG Chem
• AIMMED (Somzz)
• HoneyNaps
• Nxera Pharma (formerly Sosei Group)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea insomnia therapeutics market based on the below-mentioned segments:

South Korea Insomnia Therapeutics Market, By Type

• Benzodiazepines
• Nonbenzodiazepines
• Antidepressants
• Orexin Antagonists
• Melatonin Antagonists

South Korea Insomnia Therapeutics Market, By Sales Channel

• Over-The-Counter (OTC)
• Prescription Therapeutics